Veytics Intelligence
2026-11-07 · NASDAQ

Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?

Key PointsGLP-1 drugs might be effective in treating a wide variety of disorders.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.